Cost-Utility Analysis Of Axicabtagene Ciloleucel (Yescarta) Versus Standard Care For Relapsed Or Refractory Large B-Cell Lymphoma - Health Payer Perspective - Health care payer cost-utility analysis

Sep 29, 2026

Uploaded by Noah

A healthcare payer perspective cost-utility analysis evaluates axicabtagene ciloleucel (axi-cel; Yescarta) as a third-line therapy versus standard care for relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma in Switzerland. Direct medical costs in 2023 CHF are included, with outcomes measured in life years and quality-adjusted life years using a lifetime horizon. Costs and outcomes are discounted at 3% annually, and uncertainty is assessed via sensitivity analyses.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Introduction

Methods

Results

Conclusions

OP41 Using Horizon Scanning To Identify Emerging Quantum Technologies In Health Care Ross Fairbairn, Oshin Sharma, Imogen Forsythe, Elizabeth Green, Oleta Williams and Andrew Mkwashi ([Andrew.Mkwashi@io.nihr.ac.uk](Andrew.Mkwashi@io.nihr.ac.uk)) Introduction: Quantum technologies, driven by principles of quantum mechanics like superposition and entanglement, have shown transformative potential in health and medicine. However, the understanding of these technologies in early to late stages of development is limited. This study aimed to investigate the emerging applications of quantum technologies in health care, with a focus on quantum computing, diagnostics, and therapeutics. Methods: Horizon scanning researchers, in collaboration with information specialists and with steering from subject matter experts at National Health Service England, developed search strategies for identifying relevant emerging and established quantum applications in healthcare domains such as drug design, personalized medicine, diagnosis assistance, and treatment or interventions. We conducted a comprehensive review of this landscape by analyzing data from clinical trials, published literature, and soft intelligence sources. Primary and secondary sources were reviewed systematically using a combination of traditional methods and the Innovation Observatory’s in-house semi-automated Search Companion for Advanced News Article Retrieval (SCANAR) tool to capture non-traditional soft intelligence sources. Results: The scan identified 116quantum technologies in healthcare, with magnetoencephalography (MEG), quantum dots, and superconducting quantum interference devices (SQUIDs) being the most frequently used for brain mapping, imaging, and cardiac diagnostics. Over half (54%) of these technologies assist in diagnosis, while others are used in drug design (15%), treatment (15%), and precision medicine (13%). Quantum computing applications (28%) and quantum dots (24%) were the most common applications identified. Noncommercial trials dominated (88%), reflecting a focus on advancing care. Additionally, 27 percent of the technologies incorporate artificial intelligence, mainly for personalized medicine and imaging diagnosis. Conclusions: Quantum technologies in health care are advancing areas of diagnostics, personalized medicine, and therapeutics. Diagnostics are the most popular area, most frequently using technologies such as MEG, SQUIDs, and quantum dots. Quantum computing algorithms accelerate drug discovery and precision medicine. Although promising, integrating quantum technologies into healthcare faces challenges in infrastructure demands and regulatory frameworks, and requires professional training in quantum literacy. OP42 Cost-Utility Analysis Of Axicabtagene Ciloleucel (Yescarta) Versus Standard Care For Relapsed Or Refractory Large B-Cell Lymphoma – Health Payer Perspective Danielle Stringer, Ming Min, Konstance Nicolopoulos, Magdalena Moshi ([college.asernip@surgeons.org](college.asernip@surgeons.org)) and Thomas Vreugdenburg Introduction: Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor T-cell (CAR-T) therapy approved for relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and r/r primary mediastinal B-cell lymphoma (PMBCL) . CAR-T therapy is a type of personalized medicine that offers potentially curative options for patients with limited treatment alternatives. This study evaluated the cost effectiveness of axi-cel as a third-line therapy compared with standard care (SoC) in Switzerland. Methods: A cost-utility analysis was conducted using a healthcare payer perspective. Only direct medical costs in 2023 CHF were considered. Health outcomes were measured in life years and qualityadjusted life years. Both costs and outcomes were discounted at three percent per annum. A lifetime horizon was used to capture differences in costs and outcomes. A hybrid decision tree and three-state partitioned survival

FAQs

What therapy is assessed, and what is it compared against?

The analysis evaluates axicabtagene ciloleucel (axi-cel; Yescarta) as a third-line therapy and compares it with standard care options such as salvage chemotherapy.

How are costs and outcomes measured in the study?

Only direct medical costs in 2023 CHF are considered. Health outcomes are measured in life years and quality-adjusted life years.

What drives uncertainty in the cost-effectiveness results?

Sensitivity analyses show results depend heavily on survival extrapolations and pricing assumptions, and limited comparative evidence leads to reliance on naïve comparisons.

Sep 29, 2026

Uploaded by Noah